Dyne Therapeutics, Inc.
DYNNASDAQHealthcareBiotechnology
Previous close
$26.10
+$0.12 · +0.46%
DYN company overview
Historical prices · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
35
Expensive
Momentum
66
Gaining
Sentiment
47
Mixed
Risk resilience
56
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteDyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- John G. Cox
- Listed since
- Sep 17, 2020
- Employees
- 289
Market position
Day range
Current $26.10
52-week range
Current $26.10
- Open
- $26.20
- Previous close
- $25.98
- Volume
- 1.18M
- 0.58× average
- Average volume
- 2.04M
- Average daily volume
- Market cap
- 4.87B USD
- Beta
- 1.08
- Market reference 1
- 50-day average
- $23.5452
- +10.85% above average
- 200-day average
- $19.6123
- +33.08% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.64B USD
- EV / EBITDA
- -3.74×
- Earnings yield
- -17.76%
- Free cash flow yield
- -16.13%
Profitability & efficiency
- Return on equity
- -45.90%
- Return on assets
- -37.59%
- Return on invested capital
- -41.02%
Financial health
- Current ratio
- 22.25×
- Altman Z-score
- 7.02
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.05M USD | 2.24M USD | 2.46M USD | — | — |
| Gross profit | −2.05M USD | −2.24M USD | −2.46M USD | — | — |
| Research and development | 398.33M USD | 281.41M USD | 210.76M USD | 142.76M USD | 121.31M USD |
| Selling, general, and administrative | 69.85M USD | 62.48M USD | 31.4M USD | 28.2M USD | 28.72M USD |
| Operating expenses | 466.14M USD | 341.64M USD | 239.7M USD | 170.96M USD | 150.03M USD |
| Interest income | 29.86M USD | 26.92M USD | 7.64M USD | 2.92M USD | 742K USD |
| Interest expense | 6.19M USD | — | — | 2.92M USD | — |
| Depreciation and amortization | 2.05M USD | 2.24M USD | 2.46M USD | 1.68M USD | 1.09M USD |
| Operating income | −468.18M USD | −343.89M USD | −242.16M USD | −170.96M USD | −150.03M USD |
| Net income | −446.21M USD | −317.42M USD | −235.94M USD | −168.1M USD | −149.29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -9.01%
- 11 comparable reports
- Latest EPS result
- -1.08
- Estimate -0.75 · Miss by 44.23%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
DYN peers
Continue in GoAI
Research DYNresearch.disclaimer